通过多药理学靶向癌症激酶组。
Targeting the cancer kinome through polypharmacology.
机构信息
Zachary A. Knight is at The Rockefeller University, New York, New York 10065, USA.
出版信息
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.
Abstract
Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.
摘要
激酶抑制剂是最大的一类新型抗癌药物。然而，大多数肿瘤显然可以逃避任何单一激酶的抑制。如果需要抑制多个激酶，我们应该如何选择？在这篇观点文章中，我们讨论了目前用于确定新的激酶靶标治疗组合的一些策略。
相似文献
1
Targeting the cancer kinome through polypharmacology.
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.
2
Targeting cancer with small molecule kinase inhibitors.
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
3
The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
PLoS One. 2016 Nov 9;11(11):e0165737. doi: 10.1371/journal.pone.0165737. eCollection 2016.
4
Targeting multiple kinase pathways: a change in paradigm.
Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9.
5
Trends in kinase drug discovery: targets, indications and inhibitor design.
Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5.
6
Targeting cancer with kinase inhibitors.
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
7
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
8
Kinase drug discovery 20 years after imatinib: progress and future directions.
Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17.
9
Combining kinase inhibitors for optimally co-targeting cancer and drug escape by exploitation of drug target promiscuities.
Drug Dev Res. 2021 Feb;82(1):133-142. doi: 10.1002/ddr.21738. Epub 2020 Sep 15.
10
Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.
Mini Rev Med Chem. 2006 Oct;6(10):1101-10. doi: 10.2174/138955706778560184.
引用本文的文献
1
Polypharmacology-Driven Discovery of ZAK-I-57: A Potent Multi-Targeted Benzoxazinone Small Molecule for Hepatocellular Carcinoma Therapy.
MedComm (2020). 2025 Jul 27;6(8):e70291. doi: 10.1002/mco2.70291. eCollection 2025 Aug.
2
AI-Driven Polypharmacology in Small-Molecule Drug Discovery.
Int J Mol Sci. 2025 Jul 21;26(14):6996. doi: 10.3390/ijms26146996.
3
Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A.
EMBO J. 2025 Jun 30. doi: 10.1038/s44318-025-00490-5.
4
MADSP: predicting anti-cancer drug synergy through multi-source integration and attention-based representation learning.
Bioinformatics. 2025 Jun 2;41(6). doi: 10.1093/bioinformatics/btaf326.
5
High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach.
Molecules. 2025 May 19;30(10):2211. doi: 10.3390/molecules30102211.
6
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling.
bioRxiv. 2025 Mar 29:2025.03.26.645490. doi: 10.1101/2025.03.26.645490.
7
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment.
Cancers (Basel). 2025 Jan 7;17(2):165. doi: 10.3390/cancers17020165.
8
Discovery of Thioether-Cyclized Macrocyclic Covalent Inhibitors by mRNA Display.
J Am Chem Soc. 2024 Aug 28;146(34):24053-24060. doi: 10.1021/jacs.4c07851. Epub 2024 Aug 13.
9
Design of a covalent protein-protein interaction inhibitor of SRPKs to suppress angiogenesis and invasion of cancer cells.
Commun Chem. 2024 Jun 27;7(1):144. doi: 10.1038/s42004-024-01230-2.
10
Systematic Investigation of Dual-Target-Directed Ligands.
J Med Chem. 2024 Jun 27;67(12):10374-10385. doi: 10.1021/acs.jmedchem.4c00838. Epub 2024 Jun 6.
本文引用的文献
1
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
2
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.
3
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.
Nature. 2009 Nov 5;462(7269):104-7. doi: 10.1038/nature08462. Epub 2009 Oct 21.
4
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006.
5
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017.
6
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020.
7
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Cancer Res. 2009 May 15;69(10):4286-93. doi: 10.1158/0008-5472.CAN-08-4765. Epub 2009 Apr 28.
8
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
J Clin Oncol. 2009 Jun 10;27(17):2823-30. doi: 10.1200/JCO.2007.15.7636. Epub 2009 Apr 6.
9
Challenges and opportunities in defining the essential cancer kinome.
Sci Signal. 2009 Mar 24;2(63):pe15. doi: 10.1126/scisignal.263pe15.
10
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
Zotero 插件